November 25, 2024 at 8:41 PM
Pleasure to highlight your work with #UroToday @ravimadan.bsky.social - as we all consider how best to treat PSMA avid disease.
Do #PSMA+ findings in #BCR #ProstateCancer require immediate treatment?
NO based on emerging data @theNCI
Appreciate @tiansterzhangmd.bsky.social & #Urotoday for the opportunity to discuss
Ongoing trial of PSMA scans in BCR is still enrolling shorturl.at/36nGQ
www.urotoday.com/categories-m...
NO based on emerging data @theNCI
Appreciate @tiansterzhangmd.bsky.social & #Urotoday for the opportunity to discuss
Ongoing trial of PSMA scans in BCR is still enrolling shorturl.at/36nGQ
www.urotoday.com/categories-m...
PSMA PET in Biochemical Recurrence: When to Treat vs When to Wait - Ravi Madan
Tian Zhang interviews Ravi Madan about a prospective study monitoring PSMA PET-positive biochemically recurrent prostate cancer patients. The trial enrolls patients with PSA > 0.5 and negative convent...
www.urotoday.com
July 19, 2025 at 11:17 PM
Pleasure to highlight your work with #UroToday @ravimadan.bsky.social - as we all consider how best to treat PSMA avid disease.
📅 Aug. 20: Stay up to date on the latest advances in prostate cancer care. Join the free virtual 6th UroToday Journal Club for Patients, moderated by @dr-coops.bsky.social and featuring expert discussion. @ucsfhealth.bsky.social calendar.ucsf.edu/event/6th-ur...
6th UroToday A Journal Club for Prostate Cancer Patients
calendar.ucsf.edu
July 30, 2026 at 5:15 PM
📅 Aug. 20: Stay up to date on the latest advances in prostate cancer care. Join the free virtual 6th UroToday Journal Club for Patients, moderated by @dr-coops.bsky.social and featuring expert discussion. @ucsfhealth.bsky.social calendar.ucsf.edu/event/6th-ur...
Solving the Global BCG Shortage with ImmunityBio’s Supercharged BCG - Pat Soon-Shiong
oncodaily.com/voices/pat-s...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #BCG #ImmunityBio
oncodaily.com/voices/pat-s...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #BCG #ImmunityBio
Pat Soon-Shiong: Solving the Global BCG Shortage with ImmunityBio’s Supercharged BCG - OncoDaily
Pat Soon-Shiong: Solving the Global BCG Shortage with ImmunityBio’s Supercharged BCG / BCG, cancer, ImmunityBio, OncoDaily, Oncology, Pat Soon-Shiong, UroToday
oncodaily.com
October 31, 2025 at 1:40 PM
Solving the Global BCG Shortage with ImmunityBio’s Supercharged BCG - Pat Soon-Shiong
oncodaily.com/voices/pat-s...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #BCG #ImmunityBio
oncodaily.com/voices/pat-s...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #BCG #ImmunityBio
Hi all, something new I’ve been working on
May 17, 2026 at 3:36 PM
Hi all, something new I’ve been working on
@PavlosMsaouel @UTMDAnderson w well done investigator initiated study leveraging EGFR expression in #renalmedullary — panitumumab & Abraxane. Very important life work for a rare cancer.
@ASCO #ASCO26 @OncoAlert @urotoday
@ASCO #ASCO26 @OncoAlert @urotoday
June 1, 2026 at 2:27 PM
@PavlosMsaouel @UTMDAnderson w well done investigator initiated study leveraging EGFR expression in #renalmedullary — panitumumab & Abraxane. Very important life work for a rare cancer.
@ASCO #ASCO26 @OncoAlert @urotoday
@ASCO #ASCO26 @OncoAlert @urotoday
WCET 2025: State of the Art Lecture: Kidney in a Bag: The Next Frontier for Urologic Innovation and Discovery? - UroToday
#art
#art
UroToday
news.google.com
September 11, 2025 at 11:40 PM
WCET 2025: State of the Art Lecture: Kidney in a Bag: The Next Frontier for Urologic Innovation and Discovery? - UroToday
#art
#art
Good morning Chicago! Kidney/bladder orals today Friday @asco #ASCO26!!
Looking forward to seeing the wins for our patients with cancer, networking, and considering new trials that will make a difference. Here for all of it!!
@oncoalert @utswcancer @urotoday
Looking forward to seeing the wins for our patients with cancer, networking, and considering new trials that will make a difference. Here for all of it!!
@oncoalert @utswcancer @urotoday
May 29, 2026 at 11:57 AM
Good morning Chicago! Kidney/bladder orals today Friday @asco #ASCO26!!
Looking forward to seeing the wins for our patients with cancer, networking, and considering new trials that will make a difference. Here for all of it!!
@oncoalert @utswcancer @urotoday
Looking forward to seeing the wins for our patients with cancer, networking, and considering new trials that will make a difference. Here for all of it!!
@oncoalert @utswcancer @urotoday
Congrats to our colleagues Drs. Maria T. Diaz-Meco & Jorge Moscat on their new @urotoday 'Beyond the Abstract' supplemental commentary, "Increased Translation Driven by Non-Canonical EZH2 Creates a Synthetic Vulnerability in Enzalutamide-Resistant #ProstateCancer."
www.urotoday.com/recent-abstr...
www.urotoday.com/recent-abstr...
January 15, 2025 at 2:00 PM
Congrats to our colleagues Drs. Maria T. Diaz-Meco & Jorge Moscat on their new @urotoday 'Beyond the Abstract' supplemental commentary, "Increased Translation Driven by Non-Canonical EZH2 Creates a Synthetic Vulnerability in Enzalutamide-Resistant #ProstateCancer."
www.urotoday.com/recent-abstr...
www.urotoday.com/recent-abstr...
@shilpaonc @ClevelandClinic w #MAINCAV results — Cabo-avelumab vs avelumab in maintenance #bladdercancer. Closed after 10% pts accrued 2/2 EV-pembro landscape changes. Valiant effort from @ALLIANCE_org.
#ASCO26 @asco @oncoalert @urotoday
#ASCO26 @asco @oncoalert @urotoday
June 1, 2026 at 1:20 PM
@shilpaonc @ClevelandClinic w #MAINCAV results — Cabo-avelumab vs avelumab in maintenance #bladdercancer. Closed after 10% pts accrued 2/2 EV-pembro landscape changes. Valiant effort from @ALLIANCE_org.
#ASCO26 @asco @oncoalert @urotoday
#ASCO26 @asco @oncoalert @urotoday
@IyerGopa @MSKCancerCenter with phase 1 #NEXUS01 of nectin4 delivering topoisomerase inhibitor — ligand is still relevant for some EV-pembro refectory #bladdercancer w responses.
@asco #ASCO26 @oncoalert @urotoday
@asco #ASCO26 @oncoalert @urotoday
May 29, 2026 at 10:23 PM
@IyerGopa @MSKCancerCenter with phase 1 #NEXUS01 of nectin4 delivering topoisomerase inhibitor — ligand is still relevant for some EV-pembro refectory #bladdercancer w responses.
@asco #ASCO26 @oncoalert @urotoday
@asco #ASCO26 @oncoalert @urotoday
www.urotoday.com/video-lectur...
Engineered Salmonella as Intravesical Therapy for Recurrent Bladder Cancer - Michael Oefelein
Engineered Salmonella as Intravesical Therapy for Recurrent Bladder Cancer - Michael Oefelein
Engineered Salmonella as Intravesical Therapy for Recurrent Bladder Cancer - Michael Oefelein
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
www.urotoday.com
June 12, 2026 at 7:21 PM
www.urotoday.com/video-lectur...
Engineered Salmonella as Intravesical Therapy for Recurrent Bladder Cancer - Michael Oefelein
Engineered Salmonella as Intravesical Therapy for Recurrent Bladder Cancer - Michael Oefelein
#SUO24 Implementing Smoking Cessation in the Urologic Oncology Setting @RichMatulewicz
Urologists: the most trusted and utilized source of information regarding the cause and 🚬-related nature of the patient’s bladder ca diagnosis
@urotoday
Urologists: the most trusted and utilized source of information regarding the cause and 🚬-related nature of the patient’s bladder ca diagnosis
@urotoday
December 4, 2024 at 11:30 PM
#SUO24 Implementing Smoking Cessation in the Urologic Oncology Setting @RichMatulewicz
Urologists: the most trusted and utilized source of information regarding the cause and 🚬-related nature of the patient’s bladder ca diagnosis
@urotoday
Urologists: the most trusted and utilized source of information regarding the cause and 🚬-related nature of the patient’s bladder ca diagnosis
@urotoday
Thanks to Zach and UroToday for the opportunity to speak about this work!
www.urotoday.com/video-lectur...
www.urotoday.com/video-lectur...
Real-World Implementation of Biomarkers for Microhematuria Workup - Ronald Loo & Christopher Filson
Zachary Klaassen interviews Ron Loo and Chris Filson about integrating the urine‑based Cxbladder Triage test into microscopic hematuria evaluation across their large health system. The retrospective r...
www.urotoday.com
May 16, 2025 at 6:31 PM
Thanks to Zach and UroToday for the opportunity to speak about this work!
www.urotoday.com/video-lectur...
www.urotoday.com/video-lectur...
@asco #ASCO26 — come for the science, stay for the people. Love our connections with friends near & far through the years, tied by common passion to improve outcomes for our patients w cancer.
@oncoalert @urotoday @utswcancer @dukegucancer
@oncoalert @urotoday @utswcancer @dukegucancer
June 2, 2026 at 2:27 AM
@asco #ASCO26 — come for the science, stay for the people. Love our connections with friends near & far through the years, tied by common passion to improve outcomes for our patients w cancer.
@oncoalert @urotoday @utswcancer @dukegucancer
@oncoalert @urotoday @utswcancer @dukegucancer
Targeted versus empiric approach for prevention of recurrent kidney stones - UroToday - goo.gl/alerts/VqXAE4 #GoogleAlerts
August 25, 2026 at 7:37 PM
Targeted versus empiric approach for prevention of recurrent kidney stones - UroToday - goo.gl/alerts/VqXAE4 #GoogleAlerts
Fantastic discussion @apolo_andrea @theNCI for past/present/future of nectin4. EV pembro success in #bladdercancer also sets up a new world of challenges for resistance & sequencing approaches. @asco #ASCO26 @oncoalert @urotoday
May 29, 2026 at 10:47 PM
Fantastic discussion @apolo_andrea @theNCI for past/present/future of nectin4. EV pembro success in #bladdercancer also sets up a new world of challenges for resistance & sequencing approaches. @asco #ASCO26 @oncoalert @urotoday
Be sure to check out the latest @UroToday expert commentary "Benefits of Comprehensive Geriatric Assessment in Older Patients with Muscle-Invasive #BladderCancer," by our Chief Research Officer Dr. Bishoy M. Faltas (@FaltasLab)!
www.urotoday.com/recent-abstr...
www.urotoday.com/recent-abstr...
December 17, 2024 at 3:11 PM
Be sure to check out the latest @UroToday expert commentary "Benefits of Comprehensive Geriatric Assessment in Older Patients with Muscle-Invasive #BladderCancer," by our Chief Research Officer Dr. Bishoy M. Faltas (@FaltasLab)!
www.urotoday.com/recent-abstr...
www.urotoday.com/recent-abstr...
On UroToday + GU OncToday, Winship medical oncologist Jacqueline Brown, MD, joined a discussion on perioperative systemic therapies for muscle invasive bladder cancer.
The discussion highlights recent advances, including the NIAGARA trial. Learn more ➡️ brnw.ch/21wQHx4
The discussion highlights recent advances, including the NIAGARA trial. Learn more ➡️ brnw.ch/21wQHx4
February 14, 2025 at 6:22 PM
On UroToday + GU OncToday, Winship medical oncologist Jacqueline Brown, MD, joined a discussion on perioperative systemic therapies for muscle invasive bladder cancer.
The discussion highlights recent advances, including the NIAGARA trial. Learn more ➡️ brnw.ch/21wQHx4
The discussion highlights recent advances, including the NIAGARA trial. Learn more ➡️ brnw.ch/21wQHx4
The association between dietary intake of iodine and kidney stones - UroToday - goo.gl/alerts/FZvgiY #GoogleAlerts
June 30, 2026 at 6:50 PM
The association between dietary intake of iodine and kidney stones - UroToday - goo.gl/alerts/FZvgiY #GoogleAlerts
@CaPsurvivorship @DanaFarber_GU reports her many year #ARACOG trial — important objective measures for cognitive changes on darolutamide vs enzalutamide in #prostatecancer. Daro w improved cog fxn vs enza. Important work for ARPI selection. @asco #ASCO26 @oncoalert @urotoday
May 30, 2026 at 9:38 PM
@CaPsurvivorship @DanaFarber_GU reports her many year #ARACOG trial — important objective measures for cognitive changes on darolutamide vs enzalutamide in #prostatecancer. Daro w improved cog fxn vs enza. Important work for ARPI selection. @asco #ASCO26 @oncoalert @urotoday
August 20: Learn how the latest prostate cancer research could impact your care. Register for the free virtual 6th UroToday Journal Club for Patients featuring expert discussion and patient-focused insights. Moderated by @dr-coops.bsky.social @ucsfhealth.bsky.social calendar.ucsf.edu/event/6th-ur...
6th UroToday A Journal Club for Prostate Cancer Patients
calendar.ucsf.edu
August 14, 2026 at 5:06 PM
August 20: Learn how the latest prostate cancer research could impact your care. Register for the free virtual 6th UroToday Journal Club for Patients featuring expert discussion and patient-focused insights. Moderated by @dr-coops.bsky.social @ucsfhealth.bsky.social calendar.ucsf.edu/event/6th-ur...
Here's the latest @urotoday Expert Commentary by EIPM's Chief Research Officer Dr. Bishoy Faltas (@FaltasLab), "Efficacy and Safety of an Avelumab and Chemotherapy Combination Treatment Regimen in Cisplatin Ineligible Patients with Metastatic Urothelial Carcinoma."
www.urotoday.com/recent-abstr...
www.urotoday.com/recent-abstr...
November 22, 2024 at 2:58 PM
Here's the latest @urotoday Expert Commentary by EIPM's Chief Research Officer Dr. Bishoy Faltas (@FaltasLab), "Efficacy and Safety of an Avelumab and Chemotherapy Combination Treatment Regimen in Cisplatin Ineligible Patients with Metastatic Urothelial Carcinoma."
www.urotoday.com/recent-abstr...
www.urotoday.com/recent-abstr...
#MaryEllenTaplin @DanaFarber_GU with first plenary of the day @asco #ASCO26 — phase 3 of #PROTEUS — >2100 patients w high risk #prostatecancer, adt and apalutamide improved path CR and also a highly powered statistically significant MFS benefit.
@oncoalert @urotoday @PCF_Science
@oncoalert @urotoday @PCF_Science
May 31, 2026 at 6:42 PM
#MaryEllenTaplin @DanaFarber_GU with first plenary of the day @asco #ASCO26 — phase 3 of #PROTEUS — >2100 patients w high risk #prostatecancer, adt and apalutamide improved path CR and also a highly powered statistically significant MFS benefit.
@oncoalert @urotoday @PCF_Science
@oncoalert @urotoday @PCF_Science
@DrChoueiri presents first biomarker work from #keynote564 — ctDNA positive group only n=60 treated but poor prognosis begs question who to escalate?? And who in neg-neg group may we de-escalate treatment? @asco #ASCO26 @oncoalert @urotoday @utswcancer
May 29, 2026 at 8:19 PM
@DrChoueiri presents first biomarker work from #keynote564 — ctDNA positive group only n=60 treated but poor prognosis begs question who to escalate?? And who in neg-neg group may we de-escalate treatment? @asco #ASCO26 @oncoalert @urotoday @utswcancer